Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Global Cord Blood Corporation (CO) Q2 2020 Earnings Call Transcript

By Motley Fool Transcribers - Nov 27, 2019 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CO earnings call for the period ending September 30, 2019.

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Global Cord Blood Corporation ( CO -1.72% )
Q2 2020 Earnings Call
Nov 27, 2019, 8:00 a.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:


Ladies and gentlemen, thank you for standing by and welcome to Global Cord Blood Corporations Earnings Conference Call for the Fiscal 2020 Second Quarter. [Operator Instuctions]

Now, I would like to introduce Cathy Bai, VP of corporate finance to begin the presentation. Thank you, Cathy. Please go ahead.

Cathy Bai -- Vice President of Corporate Finance

Thank you, Anna. Good morning, everyone. Good morning, everyone. Welcome to our fiscal 2020 second quarter earnings conference call. A press release discussing our financial results has already been published and a copy is available on our company's website.

During the call, our management team will summarize corporate developments and financial highlights for the quarter. A question-and-answer session will follow.

Before we begin, please note that today's discussion will contain forward-looking statements that are subject to certain risks and uncertainties and actual results could be materially different from these forward-looking statements. Kindly refer to our SEC filings for detailed discussions of potential risks.

In the interest of time, we will begin with our CEO's remarks, followed by a detailed report of our fiscal 2020 second quarter financials given by our CFO Mr. Albert Chen. Our management will be available to answer questions during the Q&A session. In view of recent developments, we understand investors and shareholders have various questions to ask. To give everyone a chance to ask questions, we'd appreciate it if you could ask one question at a time.

Today, on behalf of our CEO Tina, I will read her prepared remarks. Let's begin our presentation.

ZHENG Ting, Tina -- Chairperson, Chief Executive Officer, Director, and Chief Executive Officer of Beijing Division

Good morning, ladies and gentlemen, welcome to our fiscal 2020 second quarter earnings conference call.

During the second fiscal quarter, consumer sentiment and behavior remained cautious under the pressure of slower economic growth in China as well as US China trade tensions. Despite this headwind, we managed to recruit 21,551 new subscribers, staying on track with our annual target. The growth was mainly derived from our Guangdong operation. By the end of the reporting quarter, our accumulated subscriber had surpassed 791,000.

In addition to enhancing sales activities and educating markets, we continued to solidify our leading position through improving operations and services in the second quarter. During the reporting quarter, Zhejiang received the American Association of Blood Banks or, AABB accreditation. Hence, all of our facilities are now accredited by AABB, in line with international standards.

Recently, the Regulation of the People's Republic of China on the Administration of Human Genetic Resources came into effect. The Regulation covers a large scope of companies that are in possession of substances containing human genes, such as organs and cells, as well as information about human genes. As announced last week, we are in the process of evaluating the implications of the Regulation, and we intend to keep investors informed of any new developments.

Looking ahead, we will continue to explore opportunities and channels to broaden our revenue sources. We will also closely monitor the impact of the macro economic environment on consumer demand of preventive healthcare services. We remain alert on any new regulatory developments in our operating markets and are ready to adjust our overall strategy and market positioning based on any potential changes. Bearing all these in mind, we remain committed to our fiscal 2020 new subscriber target, which is between 80,000 and 85,000.

This concludes my remarks regarding our fiscal 2020 second quarter results. Thank you for your ongoing support of Global Cord Blood Corporation.

I will now turn the call over to our CFO, Mr. Albert Chen, to go over our second fiscal quarter financial performance.

CHEN Bing Chuen, Albert -- Chief Financial Officer and Director

Good morning everyone. In the second quarter, revenues increased by 27% year-over-year to RMB314 million. Similar to last quarter, the increase was mainly driven by the upward adjustment in processing fees from RMB6,800 to RMB9,800, which became effective in April, 2019. In addition, storage revenues increased as a result of the Company's enlarged subscriber base.

In the reporting quarter, driven by concerns over slower economic growth as well as the on-going US-China trade tensions, consumer sentiment in our markets remained conservative. At the same time, our target segment was adjusting to the new pricing. Despite such conditions, we managed to recruit 21,551 new subscribers, in line with management expectations, at only a 6.6% year-over-year -- only at a 6% year-over-year decrease. With a boosting effect from the new processing fee, revenues generated from processing fees and other services increased by 32% year-over-year to RMB201 million. This represents approximately 64% of total revenues compared to 61% last year.

By the end of September 2019, our accumulated subscriber base had exceeded 791,000. Accordingly, storage revenues for this quarter increased by approximately 18% year-over-year to RMB113 million. Gross profit in this quarter increased by 33% year-over-year to nearly RMB265 million. Gross margin improved to 85%, as the increase in the processing fee exceeded the increase in labor related costs. Benefiting from the new pricing, operating income increased by 38% year-over-year to RMB144 million and operating margin increased to 46%. Depreciation and amortization expenses were approximately RMB13 million, similar to last year. Despite the increase in operating expenses, non-GAAP operating income still increased by 33% year-over-year to RMB157 million. Non-GAAP operating margin increased to 50%.

In the face of cautious consumer sentiment in the second quarter, we continued to expand our sales team and scaled up our marketing and promotion activities. Therefore, sales and marketing expenses increased by 26% year-over-year, or 7% quarter-over-quarter, to RMB65 million. Sales and marketing expenses as a percentage of revenues was 21%, same as last year and down from 22% of last quarter. General and administrative expenses amounted to RMB49 million compared to RMB40 million last year. The increase was mainly attributable to the increase in staff costs, bad debt provision, and legal and professional fees. That said, general and administrative expenses as a percentage of revenues decreased to less than 16%.

In the second quarter, we recognized a RMB7 million decrease in fair value of equity securities, or commonly known as mark-to-market loss. This was significantly less than the RMB31 million which was recorded last year. As a result of an increase in operating income and a significant decrease in mark-to-market loss from equity securities, income before tax increased by 78% year-over-year to RMB144 million. Net income attributable to the Company's shareholders increased by 85% year-over-year to RMB120 million. Net margin improved to 38% from 26% of last year. Basic and diluted earnings per ordinary share for the second quarter were RMB0.99.

This concludes my remarks. We are now happy to take any questions concerning our latest financial results and our recent operational developments.

Questions and Answers:


Ladies and gentlemen, we will now begin the question-and-answer session. [Operator Instructions]

Your first question is from Michael Schmitz from Jayhawk Capital. Your line is now open, sir. Please go head.

Michael Schmitz -- Jayhawk Capital Management -- Analyst

Hi, Albert. I'm not sure what technical difficulties you may have been having, but the lines didn't actually start -- weren't able to hear what you were saying until about five second before it was opened up for questions. So I don't see the repeat everything or if that was just for me. But the question I have -- the new regulation that were issued in June and they're fully addressed in your 20-F, so it's puzzling that the company felt the need to issue last week's press release, five months later, just to say that you still don't known yet of any implications from the regulations. There has been no discernible action from the special committee, that even start to evaluate the Cordlife proposal from June 4, which was about six months ago. Although the special committee has been collecting handsome fee every month for that purpose. Obviously, the most important issue that continues to be ignored by the company is how the plan to utilize the cash resources that are now and have been for some time greater than the market cap of the company.

The factor of majority owner is not chosen to remove any Board members, seems to indicate to me that they're happy with the Boards performance since shareholder value continues to be significantly depressed by any reasonable valuation metric. I can only assume they prefer to not return cash to shareholders and we'd like to keep the stock price depressed, and therefore, happy with the Board's willingness to go along with this. It was announced that the majority holder would be selling its stake in the company to Nanjing Xinjiekou Department Store, or the Asia company that's also control by Sanpower, although no terms have been disclosed yet. Since then, Mr. Yuan Yafei has actually resigned his Chairmanship of that company. And I'd appreciate any comments you can provide about that.

But my real question, just regards to use the company cash, the company and the Board should be making decisions independent of direction or anything from any particular shareholder and should instead consider only the best interest of all shareholders. The company continues to operate very well, but can the company articulate any steps they're taking from a corporate finance perspective to actually increase shareholder value? Thank you.

CHEN Bing Chuen, Albert -- Chief Financial Officer and Director

Well, let me first of all apologize, as my estimates -- it was brought to my attention that many callers have difficulty in listening to our earnings debriefing. Instead of going through the material, again, I think maybe is the -- for the best use of our everybody's time we would just make the transcript available online that may be easier for everyone.

Now my responses to Mike's questions moment ago. I think there are a couple of -- both set of questions, one of them concerning the status of the recent discussion between the company and Cordlife, the other regarding the usage of capitals and the other one that's relating to the latest regulations. I'll try to address the best I can to each of these of -- each of the three questions.

Let me begin by saying that with respect to the non-binding proposal from Cordlife, while I'm not authorized to respond to questions relating to the special committee or the proposed offer. I do understand that investor are eager to learn about the latest assessment regarding Cordlife non-binding offer. As you are aware, the committee is comprises of both new and old directors, who are independent from the offer. And they will review and evaluate this proposed offer free from conflict of interest, and will do what's in the best interest of all stakeholders. Many investors have urged the special committee to provide more information regarding the status of the proposed offer and we will reiterate the message internally as well. Rest assured, the company as well as the special committee will continue to comply with this disclosure obligation and we will make the further announcement accordingly.

As for the latest regulations, with respect to the administration's on Human Genetic Resources, I just wanted to say that, I think the regulation itself is remain ambiguous and to a certain extent, I think is rather unclear. Overall, it has a strong emphasis on genetic research. But also penalized foreign entities from obtaining super sensitive genetic information who are not in compliance with the regulation. There are many parts and section in the regulation which seem very unclear to us. And we need to really consult with different government agencies before drawing any definitive conclusions. I think at this stage, we have not obtained enough credible information to predict the impact of this speculation and how it will affect PRC-covered [Phonetic] banking industry industry in 2020 and beyond. But as stated in our press release, we are seeking many clarifications and we will keep the market informed along the way.

While this regulation can potentially impact on our strategic thinking and our expansion strategy, it does not change the factor the company's strategy going forward. And it will require some form of diversification or service extensions. So that the overall direction hasn't changed but it certainly bring forth a layer of uncertainty. And I believe that the other question is regarding how the company issued -- allocated capital given the company capital on hand. Let me begin by saying that we are constantly reviewing our capital structure and we are also looking into the different ways to deploy our capital. And there are multiple ways to deploy capital including like using the capital for growth -- organic growth or even in M&A activities, or even in dividend etc.

And we need to take into consideration the current business environment and the company long-term goal. Because of the PRC-covered banking regulatory uncertainty, we have to look at various possible scenario and compare those scenarios with the various strategy that we can implement. Taking into account what may or may not happen beyond 2020, it seems prudent to keep as many option open as possible. But once again, our strategy toward taking the Company to the next phase through continuous market penetration and at the same time exploring the possibility of exploring or expanding our service offering and to the extent, diversify our geographical risk, business concentration risk, those parameter is still balanced after that. I hope those addressed your questions.


Thank you. Our next question is from Cyrille Pichot from Altimeo. Your line is now open. Please go ahead.

Cyrille Pichot -- Altimeo -- Analyst

Yes. Hello, sir, thank you for taking my question. Just two questions, can you give us an estimation of the breakdown by region and by payment type for this quarter. And second question is, it's about the regulatory. Do you have any update about the licensing regime in China. I mean because I think it was in 2020 there will be some updates or maybe you have some information to give to your shareholders. Thank you.

CHEN Bing Chuen, Albert -- Chief Financial Officer and Director

Thank you for your questions. In terms of payment option breakdown for the second quarter of fiscal 2020, approximately 41% of new subscriber elect the normal payment option, approximately 49% of new subscribers elected the upfront payment options or we call it the bullet payment options. The rest on installment basis, it's about 10%. So this is slightly higher than our usual norms. But I think it is important to keep certain market presence, as well as certain volume ongoing for the interest -- for the long-term benefit of the near term -- for the long-term and near-term benefits of the company. So that's why we want to keep certain percentage of installments. So in terms of the licensing regime itself, it was unfortunate that I don't have any new information to share at this page. To be fair, I think it's fair to say that we don't have like conclusive evidence at this stage. But we would definitely -- if there is any new development, we'll definitely notify the market and all shareholders as quickly as possible, because we are also very eager to find out. But it is in the time of this uncertainty, given the uncertainty levels relatively high. So I think it is important that we remain flexible and keep our options open at this stage.


Thank you. [Operator Instructions]

CHEN Bing Chuen, Albert -- Chief Financial Officer and Director

Once again, we apologize to all the caller in this conference call, because of the technical difficulties, I understand some of you does not able to hear what we talked about during the result highlight as well as the CEO remarks. We will make sure that the transcript will be available shortly after this earnings call. Once again, I apologize for the technical issues.


[Operator Instructions] As there are no more further questions in the queue, I'd like to thank everyone for their time today to participate in the conference call. This concludes our conference call for today everyone. Thank you for your participation. You may all now disconnect.

Duration: 26 minutes

Call participants:

Cathy Bai -- Vice President of Corporate Finance

ZHENG Ting, Tina -- Chairperson, Chief Executive Officer, Director, and Chief Executive Officer of Beijing Division

CHEN Bing Chuen, Albert -- Chief Financial Officer and Director

Michael Schmitz -- Jayhawk Capital Management -- Analyst

Cyrille Pichot -- Altimeo -- Analyst

More CO analysis

All earnings call transcripts

AlphaStreet Logo

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Global Cord Blood Corporation Stock Quote
Global Cord Blood Corporation
$4.01 (-1.72%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.